

**American Diabetes Association**  
**Revenue Received from Pharmaceutical/Device Makers\***  
**2021**

Company/ Source		Total
<u>Abbott Diabetes Care</u>		
Total		\$ 2,188,107
<u>Amarin Pharma</u>		
Total		\$ 58,950
<u>Amgen</u>		
Total		\$ 800
<u>Ascensia</u>		
Total		\$ 63,300
<u>AstraZeneca</u>		
Total		\$ 139,839
<u>Bayer Healthcare</u>		
Total		\$ 1,037,883
<u>BD Diabetes Care</u>		
Total		\$ 61,320
<u>Boehringer-Ingelheim Pharmaceuticals</u>		
Total		\$ 156,000
<u>Dexcom</u>		
Total		\$ 185,950
<u>Eli Lilly and Company</u>		
Total		\$ 300,710
<u>Genentech Pharmaceuticals</u>		
Total		\$ 492
<u>Insulet Corporation</u>		
Total		\$ 61,739
<u>Janssen Pharmaceuticals</u>		
Total		\$ 3,000
<u>LifeScan</u>		
Total		\$ 44,232
<u>MannKind Corporation</u>		
Total		\$ 180,450
<u>Medtronic Diabetes</u>		
Total		\$ 1,233,052
<u>Merck</u>		
Total		\$ 690,376
<u>Novo Nordisk, Inc.</u>		
Total		\$ 3,110,886
<u>Pfizer Inc.</u>		
Total		\$ 151,692
<u>Provention Bio</u>		
Total		\$ 98,386

**American Diabetes Association  
Revenue Received from Pharmaceutical/Device Makers\*  
2021**

Company/ Source		Total
<u>Regereron Pharmaceuticals</u>		
Total		\$ 1,794,289
<u>Roche Diagnostics Corporation</u>		
Total		\$ 21,955
<u>Sanofi</u>		
Total		\$ 1,180,812
<u>Tandem Diabetes Care, Inc.</u>		
Total		\$ 52,900
<u>Viartis (Formerly Mylan)</u>		
Total		\$ 50,000
<u>Xeris</u>		
Total		\$ 145,300
<u>Zealand</u>		
Total		\$ 135,500
Grand Total		\$ 13,147,920

\* Preliminary draft of 2021 support, unaudited. 1.31.22